⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

NCT03107663 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Positron-Emission Tomography
Immunomodulation
Metastatic Solid Malignancies
Hodgkin Lymphoma

Interventions

DRUG: ⁸⁹Zr-Df-IAB22M2C Infusion

Sponsor

ImaginAb, Inc.